Bonum Therapeutics
Bonum Therapeutics is focused on a proven technology that utilizes regulation to create targeted, highly active, and less toxic medicines.
Bonum Therapeutics is a biotechnology research company headquartered in Seattle, Washington, United States. The team counts 21 people, down 40% over the last year. Bonum Therapeutics has a website drawing 2K monthly visits and most of the team based in USA.
Employee growth
Bonum Therapeutics grew from ~2 employees in June 2022 to 32 by July 2024, reaching 21 by August 2026, tracked weekly in Crustdata's proprietary dataset since June 2022.
Capital raised
Bonum Therapeutics has raised $121M across 3 rounds since 2021 - from a $1.2M Seed Round to a $93M Series A - most recently 123 days ago.
-
In April 2026, Bonum Therapeutics raised $26.9M in a Venture Round round.
-
In November 2022, Bonum Therapeutics raised $93M in a Series A round led by Vivo Capital, with Roche Venture Fund, RiverVest, Digitalis Ventures, Codon Capital, and 3×5 Partners participating.
-
In December 2021, Bonum Therapeutics raised $1.2M in a Seed Round round.
Investors
Bonum Therapeutics's 6 backers include leading firms such as Vivo Capital, Codon Capital, Roche Venture Fund, and 3×5 Partners.
Leadership
Bonum Therapeutics's leadership includes Founder and CEO John Mulligan, Ph.D., Vice President, Corporate Strategy & Operations Cindy Lai Yee, and Vice President, Biology Justin Killebrew.
Industries & markets
Bonum Therapeutics is classified across the following industries, categories, and markets that Crustdata tracks for competitive analysis and sector benchmarking.
See the top Biotechnology Research companies ranked by size, growth and funding.
In the news
Bonum Therapeutics has been featured in recent press coverage that Crustdata tracks to surface signals on launches, fundraising, partnerships, and other newsworthy events.
- USPTO Grants Key Mechanism of Action Patent to Bonum Therapeutics for its Conditionally Active Biologics Technology
- USPTO Grants Key Mechanism of Action Patent to Bonum Therapeutics for its Conditionally Active Biologics Technology
- Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
- Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Bonum Therapeutics Growth Score
Bonum Therapeutics has a Crustdata Growth Score of 46 out of 100, which points to steady growth. Behind the number: headcount fell 40% year over year, web traffic grew 24% quarter over quarter, and it last raised funding 4 months ago.
Bonum Therapeutics FAQs
Below are 11 of the most common questions about Bonum Therapeutics, answered with data tracked and refreshed weekly using Crustdata's proprietary dataset.